YULAM

Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the development of RNA interference (RNAi) therapeutics. Founded in 2002, the company focuses on discovering and commercializing a new class of medicines that work by silencing specific genes responsible for causing diseases. Alnylam has successfully brought multiple products to market, including Onpattro, Givlaari, Oxlumo, and Amvuttra, targeting rare genetic and metabolic conditions. Its robust pipeline extends into more prevalent diseases such as hypertension and Alzheimer's, utilizing its proprietary GalNAc-conjugate delivery technology. Headquartered in Cambridge, Massachusetts, Alnylam remains the dominant player in the RNAi space with extensive global partnerships.